Monte Rosa Therapeutics
GLUE
129 hedge funds and large institutions have $445M invested in Monte Rosa Therapeutics in 2025 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 35 increasing their positions, 41 reducing their positions, and 14 closing their positions.
93% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 14
59% more capital invested
Capital invested by funds: $281M → $445M (+$165M)
11% more funds holding
Funds holding: 116 → 129 (+13)
3.92% less ownership
Funds ownership: 101.14% → 97.22% (-3.9%)
15% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 41
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
53% less call options, than puts
Call options by funds: $1.84M | Put options by funds: $3.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$4.24M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$3.68M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.78M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$2.42M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$2.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$16.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.94M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$3M |
| 4 |
Goldman Sachs
New York
|
-$1.31M |
| 5 |
Renaissance Technologies
New York
|
-$1.16M |
GLUE Hedge Fund Activity: Q3 2025 in Review
129 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q3 2025, worth a combined $445M — up 59% from $281M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new GLUE positions and 14 closed out — a net gain of 13 holders — while 35 added to existing stakes and 41 trimmed.
The largest buyer was Vestal Point Capital, opening a new position worth an estimated $4.24M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $16.8M sold.
- 129 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q3 2025, up from 116 in Q2 2025.
- Funds reported $445M of Monte Rosa Therapeutics stock for Q3 2025, up 59% quarter-over-quarter.
- 27 funds opened new Monte Rosa Therapeutics positions in Q3 2025 and 14 closed out, a net change of +13 holders.
- The largest Monte Rosa Therapeutics buyer in Q3 2025 was Vestal Point Capital, an estimated $4.24M added.
- The largest Monte Rosa Therapeutics seller in Q3 2025 was Avoro Capital Advisors, an estimated $16.8M sold.
Based on aggregated 13F filings for Q3 2025.